🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Zanidatamab plus chemotherapy as first-line treatment for HER2-positive GC/GEJ cancer The Lancet Oncology doi.org/10.1016/S1470-… 🔎single-arm, phs 2 👉ORR 76·2% 👉mPFS 12·5 mo 👉mOS 36·5 mo 🧐Looks promising, now combo w/ ICI, phs-3 awaited ESMO - Eur. Oncology

"CytoDyn Announces Encouraging Survival Data in Patients with metastatic Colorectal Cancer Previously Treated with Leronlimab. Benjamin Weinberg, MD, FACP, Associate Professor at Georgetown Lombardi and Principal Investigator of CytoDyn's colorectal cancer ("CRC") program, will present the

MiniOral Session ESMO - Eur. Oncology #ESMOGI25 Innovation in #PDAC 1.- BXCL701+Pembro 2L: ORR 17% 2.- LSTA1 + GemNabPaclitaxel 1L: ORR 45%

.Benjamin Weinberg, MD, FACP presents the EXPEL PANC trial: 2nd line pembro + BXCL701 in metastatic #pancreaticcancer: 17% response rate, 39% disease control rate, PFS 2.3 months, OS not reached, 3 patients progression free > 6 months, hope on the horizon for #immunotherapy in panc

📌 ESMO - Eur. Oncology GI 2025 Highlights: BXCL701 + Pembrolizumab in Second-Line Advanced PDAC The EXPEL PANC Phase II trial (NCT05558982), presented by Dr. Benjamin Weinberg, MD, FACP from Georgetown University Medical Center at the ESMO Gastrointestinal (GI) Cancers Congress 2025 in Barcelona,

Happy to share that I was promoted to full Professor of Clinical Medicine this week at UC San Diego Health Sciences UC San Diego Health Moores Cancer Center These don’t mean much for most of the population but for us #academic s it’s something we work pretty hard to achieve. ☺️

It was lovely speaking to Benjamin Weinberg, MD, FACP (Georgetown University) who shared findings on BXCL701 plus pembrolizumab efficacy and safety in 2L advanced #PDAC, plus insights on current second-line treatment decision-making and therapeutic selection factors Watch at VJOncology.com 👀

Thank you to Benjamin Weinberg, MD, FACP of Georgetown Lombardi, for joining us at #ESMOGI25 to discuss his presentation on the preliminary efficacy and safety of BXCL701 with pembrolizumab in microsatellite-stable mPDAC. 🔗 Follow along for the latest updates: hubs.li/Q03vLGYK0

Tumor microenvironment of patients with CLDN18.2 H in GEJ/gastric cancers. Real world data Caris Life Sciences Aakash Desai, MD, MPH, FASCO Bassel El-Rayes, MD UAB O'Neal Comprehensive Cancer Center Thanks to #ESMOGI25 for extending a merit award to present our work.

Watch Benjamin Weinberg, MD, FACP of Georgetown Lombardi discuss preliminary efficacy and safety findings from BXCL701 with pembrolizumab in microsatellite-stable mPDAC. #ESMOGI25 #oncology Watch the full video here: hubs.ly/Q03vLWP90

🧵NEW VIDEO: Benjamin Weinberg, MD, FACP (Georgetown University) discusses promising early results from the EXPEL-PANC trial combining BXCL701 + pembrolizumab in 2nd-line advanced #PancreaticCancer Watch here ➡️tinyurl.com/2w26f5v9 Key highlights: ✅ Clinical activity observed in subset of

⁦Daniel Ahn⁩ from ⁦Mayo Clinic Comprehensive Cancer Center⁩ presenting positive results for his study with #parp inhibitor Olaparib in #HRR #cholangiocarcinoma ⁦ESMO - Eur. Oncology⁩ #esmogi25 ⁦Cholangiocarcinoma Foundation⁩ ⁦Milind Javle⁩ ⁦Mitesh Borad, M.D.⁩

We present the #FiveUnder5 🕘, your go-to roundup of the top 5️⃣ #oncology videos of the week. View the clips 📹: hubs.li/Q03vZt400 Icahn School of Medicine at Mount Sinai Cleveland Clinic Eileen M O’Reilly Memorial Sloan Kettering Cancer Center Katherine Ansley, MD Wake Forest University School of Medicine Benjamin Weinberg, MD, FACP Georgetown Lombardi

Explore the latest advancements in pancreatic cancer treatment, focusing on genetic mutations, targeted therapies, and emerging clinical strategies. #pancsm | Benjamin Weinberg, MD, FACP cancernetwork.com/view/3-things-…

PanCAN is proud to announce new appointments and transitions within its Board of Directors and Scientific and Medical Advisory Board (SMAB). Joining the Board this year is Jon Mahrt, Chief Executive Officer of Optum Rx and Chief Growth Officer of Optum, a leading health

Honored and humbled to accept a new role as Division Chief for Hematology & Oncology at Georgetown starting next month. Excited for all that the future holds for Georgetown University Georgetown Lombardi with the best colleagues one could ask for.

Fresh off the press! Benjamin Weinberg, MD, FACP Reetu Mukherji, MD Marcus S. Noel John Marshall Ruth He, MD, PhD , Thanks for your contribution to this project. Special thanks to Dr.Narayanan Sadagopan, our graduating fellow. nam02.safelinks.protection.outlook.com/?url=https%3A%….

.Benjamin Weinberg, MD, FACP, discussed early results from the phase 2 EXPEL PANC trial (NCT05558982), evaluating BXCL701 plus pembrolizumab (Keytruda) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) after progression on chemotherapy. onclive.com/view/five-unde… via @onclive

🎥Benjamin Weinberg, MD, FACP of Georgetown discusses CCR5 inhibition in mCRC. Leronlimab, repurposed from HIV, may reprogram “cold” tumors. New trial tests it with trifluridine/tipiracil + bevacizumab: ➡️ow.ly/KMYc50Wpm8x⬅️ ESMO - Eur. Oncology #ESMOGI25 #CRCsm #ImmunoOnc This video is

.Benjamin Weinberg, MD, FACP on the Implications of Data With BXCL701 Plus Pembrolizumab in mPDAC onclive.com/view/dr-weinbe… via @onclive